Sage Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge United Kingdom (2010)

Organization Overview

First Clinical Trial
2014
NCT02052739
First Marketed Drug
2019
brexanolone (Zulresso)
First NDA Approval
2019
brexanolone (Zulresso)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Sage Bionetworks | SAGE THERAP | Sage Therapeutics

Active Ingredients

Marketed Drugs (2)

brexanolone (Zulresso) (2019 NDA)

zuranolone (ZURZUVAE) (2023 NDA)

Drugs in Phase 4 Trials (1)

brexanolone (Zulresso) (17 trials)

Drugs in Phase 3 Trials (3)

sage-718 (11 trials)

sertraline (zoloft) (1 trial)

zuranolone (ZURZUVAE) (14 trials)

Drugs in Phase 2 Trials (2)

levodopa (larodopa) (1 trial)

sage-324 (3 trials)

Drugs in Phase 1 Trials (2)

ketamine (ketalar) (2 trials)

sage-904 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Alzheimer Disease (Phase 2)

Bipolar Disorder (Phase 2)

Cognitive Dysfunction (Phase 2)

Dementia (Phase 2)

Depression (Phase 4)

Depression, Postpartum (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 3)

Disease (Phase 3)

Essential Tremor (Phase 2)

Huntington Disease (Phase 1)

Parkinson Disease (Phase 2)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 3)

Status Epilepticus (Phase 3)

Syndrome (Phase 3)

Tremor (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 47
  • # of Trial APIs: 8